Australia Approves Remdesivir for Severe COVID-19 Patients

Australia’s Therapeutics Goods Administration (TGA) granted provisional approval to Gilead Sciences’ remdesivir for treatment of adults and children with severe COVID-19.

Marketed as Veklury, remdesivir will be available to hospitalized patients who are severely sick, or require oxygen or ventilation to breathe.

Gilead can apply for full approval when additional data confirm its safety and efficacy. The provisional approval is good for six years.